Beta Bionics Inc

Since our inception, we have incurred significant operating losses. To date, research and development, market development and commercial launch activities have accounted for a significant portion of our overall operating expenses. We expect to incur significant expenses and operating losses for the foreseeable future as we advance the commercialization of our iLet, including future development of the patch pump and bihormonal configuration of the iLet.

To date, we have funded our operations primarily with proceeds from the sale of our convertible preferred stock, raising an aggregate of approximately $356.6 million of gross proceeds, including net proceeds of approximately $101.7 million from the issuance and sale of our Series D convertible preferred stock in August 2023 and approximately $59.7 million from the issuance and sale of our Series E convertible preferred stock in November 2024. In January 2025, we completed our initial public offering and a concurrent private placement, pursuant to which we received aggregate net proceeds of approximately $190.4 million and approximately $15.6 million, respectively, in each case after deducting underwriting discounts, commissions, and other offering expenses. We have also received payments in connection with collaboration agreements and government grants, receiving $6.1 million to date from these types of arrangements, as well as from the sale of the iLet and single-use products utilized with the iLet from our contracts with customers. As of March 31, 2025, we had cash, cash equivalents and short-term and long-term investments of $295.5 million.

Cash Flows

The following table summarizes our cash flows for the periods presented:

Operating Activities

During the three months ended March 31, 2025, net cash used in operating activities was $20.0 million, primarily resulting from our net loss of $28.7 million and net cash used by changes in our operating assets and liabilities of $6.5 million. This was partially offset by non-cash charges of $15.2 million, including $12.5 million attributable to the change in fair value of our warrant liabilities as a result of the remeasurement, $2.8 million in stock-based compensation expense due to increase in headcount, $0.3 million in amortization of operating lease right-of-use asset, $0.3 million in depreciation expense, $0.1 million in provision for excess and obsolete inventory and $0.1 million in provision for net realizable value of inventory, partially offset by the $0.9 million in accretion of discount on short-term investments. Changes in our operating assets and liabilities for the three months ended March 31, 2025 are primarily attributable to a $2.6 million increase in inventories from the growth in commercial sales. Additionally, there was a $1.6 million increase in prepaid expenses and other current assets attributable to directors and officers insurance premiums, prepaid material components, and software license renewals, a $0.1 million increase in accounts payable, a $5.3 million decrease in accrued expenses and other current liabilities from the payout of the 2024 accrual bonus, and a $0.3 million decrease in operating lease liabilities. These were partially offset by a $2.9 million decrease in accounts receivable due to collections and a $0.5 million increase in deferred revenue.

During the three months ended March 31, 2024, net cash used in operations was $12.1 million, primarily attributable to our net loss of $12.4 million and net cash used by changes in our operating assets and liabilities of $4.9 million. The net cash used by changes in our operating assets and liabilities was partially offset by non-cash charges of $5.2 million, including $4.1 million attributable to the change in the fair value of our warrant liabilities during the year, $1.4 million in stock-based compensation expense due to increase in headcount, $0.3 million in depreciation expense and $0.3 million in amortization of operating lease right-of-use asset, partially offset by the $0.9 million in accretion of discount on short-term investments. For three months ended March 31, 2024, net cash used from changes in our operating assets and liabilities was primarily attributable to a $1.9 million increase in accounts receivable due to an increase in commercial sales of the iLet and a $2.4 million increase in inventories from the growth in commercial sales. Additionally, there was a $1.1 million increase in prepaid expenses and other current assets attributable to prepaid material components, software license renewals and clinical supply purchases, a $0.2 million decrease in accrued expenses and other current liabilities and a $0.2 million decrease in operating lease liabilities. These were partially offset by a $0.4 million increase in accounts payable and a $0.5 million increase in deferred revenue.

Investing Activities

During the three months ended March 31, 2025, net cash used in investing activities was $179.1 million, primarily attributable to $142.9 million in purchases of short-term investments and $63.9 million in purchases of long-term investments based on the proceeds received from our IPO in January 2025 as well as $0.3 million in additional investment in property and equipment for additional manufacturing equipment, offset by a $28.0 million in proceeds from maturities and redemptions of short-term investments.

During the three months ended March 31, 2024, net cash used in investing activities was $7.6 million, primarily attributable to a $8.0 million in proceeds from maturities and redemptions of short-term investments, offset by $0.4 million in purchases of short-term investments.

Financing Activities

During thethree months ended March 31, 2025, net cash provided by financing activities was $211.1 million, primarily attributable to the net proceeds of $195.4 million received from our IPO and $15.6 million from the private placement.

During the three months ended March 31, 2024, net cash provided by financing activities was $6,000 related to the exercise of stock options to purchase shares of our common stock.